EQUITY RESEARCH MEMO
28Bio
Generated 5/10/2026
Executive Summary
Conviction (model self-assessment)65/100
28Bio is a biotechnology company leveraging tissue engineering, neural interfacing, and artificial intelligence to create functional human brain and peripheral nervous system organoids. Its Nexon™ platform aims to address the high failure rates in central nervous system (CNS) drug development by providing human-relevant, functional data on safety and efficacy before first-in-human trials. Founded in 2020 and based in Cambridge, MA, the company is privately held and focuses on oncology and immunology applications of its organoid technology.
Upcoming Catalysts (preview)
- Q2 2026Series A Financing Round70% success
- Q4 2026Strategic Partnership with Major Pharma60% success
- Q3 2026Peer-Reviewed Publication of Nexon Platform Validation75% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)